Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light (2016)

Peer-Reviewed Study · Fryk JJ; Marks DC; Hobson-Peters J; Prow NA; Watterson D; Hall RA; Young PR; Reichenberg S; Sumian C; Faddy HM · July 25, 2016

Fryk JJ et al., 2016-07-25: Australian spike study of all four dengue serotypes and chikungunya in pooled plasma: at least 4.46-log reduction, reaching assay detection limits at 60 J/cm2, with clear dose dependence.

Treatment of plasma with the THERAFLEX MB-Plasma system resulted in at least a 4.46-log reduction in all DENV serotypes and CHIKV infectious virus.

Abstract

Fryk JJ et al., 2016-07-25: Australian spike study of all four dengue serotypes and chikungunya in pooled plasma: at least 4.46-log reduction, reaching assay detection limits at 60 J/cm2, with clear dose dependence. Study type: in vitro spiking study on pooled plasma; no human subjects. Country: Australia (Australian Red Cross Blood Service) with Macopharma co-authors. Light: 630 nm at 20, 40, 60 and 120 J/cm2 (120 J/cm2 described as the standard dose). MB concentration per the THERAFLEX process, not in the abstract. Funding/COI not in retrieved abstract record, but two co-authors are Macopharma employees (Reichenberg, Sumian) , a manufacturer interest the verifier should note. Study type: lab.